Nephros Inc - NEPH STOCK NEWS

Nephros, Inc. (NASDAQ: NEPH) will present at the LD 500 virtual investor conference on September 1, 2020, at 10:20 am ET. CEO Andy Astor will share insights about the company's advanced water purification and pathogen detection systems designed for medical and commercial markets. The LD 500 conference runs from September 1 to 4, 2020, and registration is available online. Nephros aims to continue its commitment to infection control and water safety through its innovative ultrafilters and detection systems.

Nephros (Nasdaq: NEPH) announces a leadership transition, appointing Andy Astor as President and CEO effective August 24, 2020. Daron Evans, the current CEO, will continue as Senior Science Advisor and CEO of Specialty Renal Products. Astor, who joined Nephros in 2017, has played a pivotal role in revenue growth by four-fold and fostering strong investor relations. With over 1,100 active customer sites, the company focuses on water purification and pathogen detection systems, key to infection control in healthcare settings.

Nephros, Inc. (Nasdaq:NEPH) reported a net revenue of $1.6 million for Q2 2020, down 32% from $2.3 million in 2019 due to COVID-19 interruptions. The consolidated net loss increased to $1.7 million from $0.9 million year-over-year, and adjusted EBITDA was ($1.4 million), compared to ($0.5 million) in 2019. Despite these challenges, CEO Daron Evans expressed optimism about future growth, citing early Q3 market signs and new product developments like SequaPath™ and DialyPath™. The company maintains a cash position of $7.0 million.

Nephros, a company specializing in water purification and pathogen detection systems, will release its second quarter 2020 financial results on August 5, 2020. The management will host a conference call at 4:30 PM ET to discuss these results and provide a business overview. Interested parties can join by calling 1-844-808-7106 (domestic) or 1-412-317-5285 (international). A replay will be available until August 12, 2020.

Nephros’s products include ultrafilters for medical facilities and commercial filters aimed at improving water quality.

Nephros announced findings from a study utilizing its SequaPath microbial screening system, evaluating 88 water samples across four US regions, highlighting the necessity of assessing microbial community structures in buildings previously unoccupied due to COVID-19.

Bacterial counts in stagnant water samples from unoccupied buildings were found to be up to 1,400 times higher than those in occupied spaces. The study revealed that over 50 bacterial genera, which may include pathogens, were detected in about 60% of unoccupied samples, emphasizing that tests focusing solely on Legionella are insufficient for ensuring safety.

Nephros, a commercial-stage company specializing in high-performance water purification and pathogen detection systems, announces its participation in the upcoming Zooming with LD event on July 23rd, 2020, at 11:00 AM ET. Daron Evans, President & CEO, and Andy Astor, COO & CFO, will present and address investor inquiries. Interested parties can register for the virtual presentation through the provided link. Nephros's products, including ultrafilters and pathogen detection systems, enhance infection control and water quality across various markets, including healthcare and food service.

Nephros anticipates $1.6 million in net revenues for Q2 2020, marking a 33% decline compared to the same quarter in 2019. The company ended the quarter with approximately $7.0 million in cash. This revenue decrease halted a four-year growth streak, largely attributed to COVID-19 challenges. CEO Daron Evans expressed optimism about future growth, citing rising focus on pathogens beyond COVID-19 and promising products like PluraPath, SequaPath, and DialyPath. However, there are risks related to delays in customer acquisitions due to potential new COVID-19 restrictions.

Nephros, a water purification and pathogen detection company, announced its inclusion in the Russell Microcap® Index effective June 29, 2020. This recognition is seen as a significant milestone in its growth trajectory, expected to enhance Nephros' visibility and expand its shareholder base. Inclusion in the Russell index supports the company's stature among institutional investors, with approximately $9 trillion in assets benchmarked against Russell's indexes. The company develops ultrafilters used in hospitals and pathogen detection systems for real-time water quality monitoring.

Nephros, Inc. (Nasdaq: NEPH) announced its participation in the Virtual Summer Summit scheduled for June 9, 2020, at 10:55 AM ET. Andy Astor, the company's COO & CFO, will present and field questions from investors. Nephros specializes in high-performance water purification products and pathogen detection systems for medical and commercial markets, including hospitals and dialysis centers. Interested parties can access the webcast presentation and register for the event via Nephros's official links.